17 April 2020
Catabasis Pharmaceuticals will present information on the Edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session later this month.
Edasalonexent is being developed as a potential foundational therapy aimed at improving the lives of all patients affected by DMD, regardless of their underlying mutation.
To learn about the poster session: https://www.businesswire.com/news/home/20200417005027/en/Catabasis-Pharmaceuticals-Present-2020-Muscular-Dystrophy-Association
To read more about Edasalonexent:
